Author Archives: Forest Ray PhD

9 Meters Acquires Investigational Therapy NM-136

9 Meters Biopharma acquired global development rights to NM-136, a potential Prader-Willi syndrome (PWS) therapy, from its maker, Lobesity. The therapy candidate, formerly known as LOB-0136, aims to reduce obesity among PWS patients by targeting the glucose-dependent insulinotropic polypeptide (GIP), a molecule that helps sugar enter fat cells.

New Trial for DCCR Still Favored by FDA, But Fresh Evidence Welcome

An additional clinical trial into diazoxide choline controlled release (DCCR) tablets as a potential treatment for the insatiable hunger associated with Prader-Willi syndrome (PWS) continues to be seen as necessary by U.S. Food and Drug Administration (FDA) to support a request for DCCR’s approval. But the agency also encouraged Soleno…

Review of Intranasal LV-101 Therapy Gets FDA Priority Status

The U.S. Food and Drug Administration (FDA) has granted priority review to LV-101 (intranasal carbetocin), an investigational treatment for the distress behaviors and insatiable hunger that accompany Prader-Willi syndrome (PWS). The decision reduces the review period for the medication’s new drug application (NDA) to six months, down from the…

FPWR Invests in Aardvark, Gut-targeting PWS Therapy ARD-101

The Foundation for Prader-Willi Research (FPWR) announced its support for ARD-101, an investigational, gut-targeting Prader-Willi syndrome (PWS) therapy, by investing in Aardvark Therapeutics, the treatment’s developer. “FPWR is committed to advancing the development of innovative treatments through multiple channels,” John Walter, CEO of FPWR, said in a…

Excessive Eating Affects Caregiver Burden in PWS

The excessive eating experienced by people with Prader-Willi syndrome (PWS) intimately affects the burden felt by their caregivers, according to a recent study. While this comes as no surprise to caregivers, the finding provides some of the first direct evidence of this relationship, which can inform future studies. The…